Denali Therapeutics Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Denali Therapeutics's estimated annual revenue is currently $129M per year.
- Denali Therapeutics received $130.0M in venture funding in August 2016.
- Denali Therapeutics's estimated revenue per employee is $440,273
- Denali Therapeutics's total funding is $597M.
- Denali Therapeutics has 293 Employees.
- Denali Therapeutics grew their employee count by 9% last year.
- Denali Therapeutics currently has 24 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
|Advanced Cell D...||$28.7M||185||8%||N/A||-||N/A|
|The J. Craig Ve...||$39.4M||254||N/A||N/A||-||N/A|
What Is Denali Therapeutics?
Denali Therapeutics Inc. (Denali) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).keywords:Biotechnology,Cleantech,Healthcare,Medical Diagnostics,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
Denali Therapeutics News
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson's Disease and Launch of Its Engage ...
GSA Capital Partners LLP increased its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 174.3% in the second quarter, according to its ...
Denali Therapeutics Inc. (NASDAQ: DNLI) today announced initiation of dosing in a Phase 1b clinical study of LRRK2 inhibitor DNL151 in ...
Denali Therapeutics Funding
Denali Therapeutics Executive Hires
|2015-07-23||Carole Ho||Chief Medical Officer/Head of Development||Article|
|2018-08-08||Dana Andersen||Chief Technical and Manufacturing Officer||Article|